Soleymanian Tayebeh, Kokabeh Zeinab, Ramaghi Rozita, Mahjoub Alireza, Argani Hassan
Nephrology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Nephrology Research Center, Shariati Hospital, Tehran University of Medical Sciences-International Branch, Tehran, Iran.
J Nephropathol. 2017 Mar;6(2):81-89. doi: 10.15171/jnp.2017.14. Epub 2016 Dec 14.
Diabetes is the leading cause of end stage renal disease (ESRD) worldwide.
We compared the clinical outcomes in diabetic patients on hemodialysis (HD) with non-diabetics.
Adult maintenance HD patients (N= 532) from 9 HD facilities were enrolled to this prospective cohort study in September 2012. Causes of death, hospitalization, and HD exit were recorded in a median 28 months follow up period.
Forty-one percent of patients were diabetic. Diabetic patients compared to non-diabetics had significantly higher age (62.2 ± 11.2 versus 53.1 ± 16.7 years), lower dialysis duration (median: 23 versus 30 months), more cardiovascular comorbidities (64% versus 28%) , higher C-reactive protein (CRP) levels (median: 3.80 versus 2.25 mg/L), lower serum albumin (3.86 ± 0.35 versus 3.93 ± 0.35 g/dL), lower intact parathyroid hormone (iPTH) (median: 272 versus 374 ρg/mL), higher serum triglyceride (167 ± 91 versus 139 ± 67 mg/dL) and low density lipoprotein (LDL) (82.5 ± 24.5 versus 77.5 ± 23.8 mg/dL), and worse short form health survey (SF36) score (45.7 ± 20.9 versus 52.7 ± 20.5). Annual admission rate was higher in diabetics (median: 0.86 versus 0.43) and diabetic foot involved 16% of their admissions. Transplantation rate was 4 and 9 per 100 patient years in diabetics and non-diabetics, respectively. Death rate was two folds higher in diabetics (24 versus 12 per 100 patient years). Cardiovascular diseases ( ± infections/other causes) comprised 80.5% of death in diabetics and 54.5% in non-diabetics. In Cox regression proportional hazard multivariate analysis, hazard risk of death in diabetics was 1.9 times higher than non-diabetics.
Clinical outcomes and health related quality of life (HRQOL) are much worse in diabetic compared to non-diabetic HD patients mainly due to more frequent of cardiovascular diseases (CVDs).
糖尿病是全球终末期肾病(ESRD)的主要病因。
我们比较了接受血液透析(HD)的糖尿病患者与非糖尿病患者的临床结局。
2012年9月,来自9个血液透析机构的成年维持性血液透析患者(N = 532)被纳入这项前瞻性队列研究。在中位28个月的随访期内记录死亡、住院和退出血液透析的原因。
41%的患者患有糖尿病。与非糖尿病患者相比,糖尿病患者年龄显著更大(62.2±11.2岁对53.1±16.7岁),透析时间更短(中位值:23个月对30个月),心血管合并症更多(64%对28%),C反应蛋白(CRP)水平更高(中位值:3.80mg/L对2.25mg/L),血清白蛋白更低(3.86±0.35g/dL对3.93±0.35g/dL),完整甲状旁腺激素(iPTH)更低(中位值:272pg/mL对374pg/mL),血清甘油三酯更高(167±91mg/dL对139±67mg/dL)和低密度脂蛋白(LDL)更高(82.5±24.5mg/dL对77.5±23.8mg/dL),健康调查简表(SF36)评分更差(45.7±20.9对52.7±20.5)。糖尿病患者的年住院率更高(中位值:0.86对0.43),糖尿病足占其住院病例的16%。糖尿病患者和非糖尿病患者的移植率分别为每100患者年4例和9例。糖尿病患者的死亡率高出两倍(每100患者年24例对12例)。心血管疾病(±感染/其他原因)占糖尿病患者死亡的80.5%,占非糖尿病患者死亡的54.5%。在Cox回归比例风险多变量分析中,糖尿病患者的死亡风险比非糖尿病患者高1.9倍。
与非糖尿病血液透析患者相比,糖尿病患者的临床结局和健康相关生活质量(HRQOL)更差,主要原因是心血管疾病(CVDs)更常见。